Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8176 to 8190 of 8899 results

  1. Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) (TA652)

    This guidance has been updated and replaced by NICE technology appraisal guidance 816.

    Withdrawn guidance

  2. The clinical effectiveness and cost effectiveness of new drugs for bipolar disorder (TA66)

    This guidance has been updated and replaced NICE guideline CG38.

    Withdrawn guidance

  3. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)

    This guidance has been updated and replaced by NICE technology appraisal guidance 836.

    Withdrawn guidance

  4. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer (TA62)

    This appraisal has been updated and replaced by NICE guideline CG81.

    Withdrawn guidance

  5. Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA620)

    This guidance has been updated and replaced by NICE technology appraisal guidance 908.

    Withdrawn guidance

  6. Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies (TA669)

    This guidance has been updated and replaced by NICE technology appraisal guidance 852.

    Withdrawn guidance

  7. The clinical effectiveness and cost effectiveness of amantadine and oseltamivir for the prophylaxis of influenza (TA67)

    This guidance has been updated and replaced NICE technology appraisal guidance 158.

    Withdrawn guidance

  8. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1119.

    Withdrawn guidance

  9. Newer drugs for epilepsy in children (TA79)

    This guideline has been updated and replaced by NICE guideline CG137.

    Withdrawn guidance

  10. Hearing disability - hearing aids (TA8)

    This guidance has been withdrawn.

    Withdrawn guidance

  11. Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80)

    This guidance has been replaced by recommendations 1.3.4 to 1.3.8 in NICE guideline CG94 and by recommendation 1.3.18 in NICE guideline CG172.

    Withdrawn guidance

  12. Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1038.

    Withdrawn guidance

  13. Crizanlizumab for preventing sickle cell crises in sickle cell disease (TA743)

    NICE has withdrawn this guidance. Novartis will stop marketing crizanlizumab (Adakveo) because its marketing authorisation has been withdrawn by the Medicines and Healthcare products Regulatory Agency (MHRA). Novartis has issued a direct letter to healthcare professionals specialising in haematology. No new people will start taking crizanlizumab in the UK. Healthcare professionals should discuss alternative treatment options with people currently having crizanlizumab.

    Withdrawn guidance

  14. Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1018.

    Withdrawn guidance

  15. Fostamatinib for treating refractory chronic immune thrombocytopenia (TA759)

    This guidance has been updated and replaced by NICE technology appraisal guidance 835.

    Withdrawn guidance